Determining the accuracy of next generation sequencing based copy number variation analysis in Hereditary Breast and Ovarian Cancer

Nihat Bugra Agaoglu*, Busra Unal, Ozlem Akgun Dogan, Payam Zolfagharian, Pari Sharifli, Aylin Karakurt, Burak Can Senay, Tugba Kizilboga, Jale Yildiz, Gizem Dinler Doganay, Levent Doganay

*Bu çalışma için yazışmadan sorumlu yazar

Araştırma sonucu: ???type-name???Makalebilirkişi

2 Atıf (Scopus)

Özet

Background: Copy number variations (CNVs) are commonly associated with malignancies, including hereditary breast and ovarian cancers. Next generation sequencing (NGS) provides solutions for CNV detection in a single run. This study aimed to compare the accuracy of CNV detection by NGS analyzing tool against Multiplex Ligation Dependent Probe Amplification (MLPA). Research design and methods: In total, 1276 cases were studied by targeted NGS panels and 691 cases (61 calls in 58 NGS-CNV positive and 633 NGS-CNV negative cases) were validated by MLPA. Results: Twenty-eight (46%) NGS-CNV positive calls were consistent, whereas 33 (54%) calls showed discordance with MLPA. Two cases were detected as SNV by the NGS and CNV by the MLPA analysis. In total, 2% of the cases showed an MLPA confirmed CNV region in BRCA1/2. The results of this study showed that despite the high false positive call rate of the NGS-CNV algorithm, there were no false negative calls. The cases that were determined to be negative by the NGS and positive by the MLPA were actually carrying SNVs that were located on the MLPA probe binding sites. Conclusion: The diagnostic performance of NGS-CNV analysis is promising; however, the need for confirmation by different methods remains.

Orijinal dilİngilizce
Sayfa (başlangıç-bitiş)239-246
Sayfa sayısı8
DergiExpert Review of Molecular Diagnostics
Hacim22
Basın numarası2
DOI'lar
Yayın durumuYayınlandı - 2022

Bibliyografik not

Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.

Finansman

The authors would like to thank Sarah Frazier for language editing. This study was partially supported by Istanbul Development Agency (IDA). Project Number: YNY2016/144258

FinansörlerFinansör numarası
Istanbul Kalkinma AjansiYNY2016/144258

    Parmak izi

    Determining the accuracy of next generation sequencing based copy number variation analysis in Hereditary Breast and Ovarian Cancer' araştırma başlıklarına git. Birlikte benzersiz bir parmak izi oluştururlar.

    Alıntı Yap